S. 79 · 118th Congress (2023–2025)
Interagency Patent Coordination and Improvement Act of 2023
This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.
The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the PTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the PTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the PTO, and (3) the PTO to assist the FDA in its ministerial role of listing patents.
Show official title
A bill to amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReported by committee
This bill’s path
This is S. 79’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Richard J. Durbin (D-IL)
- Cosponsors
5 cosponsors
3 original · 2 later
- Sen. Christopher A. Coons (D-DE)· Original · Jan 25, 2023
- Sen. Chuck Grassley (R-IA)· Original · Jan 25, 2023
- Sen. Thom Tillis (R-NC)· Original · Jan 25, 2023
- Sen. Dianne Feinstein (D-CA)· Later · Feb 7, 2023
- Sen. Peter Welch (D-VT)· Later · Feb 7, 2023
- Policy area
- Commerce
- Subjects
- Administrative remedies
- Department of Commerce
- Drug safety, medical device, and laboratory regulation
- Food and Drug Administration (FDA)
- Intellectual property
- Intergovernmental relations
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
▸ 3 committee actions · Jan 25, 2023 – Mar 1, 2023
Referred to committee
Read twice and referred to the Committee on the Judiciary.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Reported by committee → No further action before the 118th Congress ended.
Committees
Feb 9, 2023 · Meeting
Feb 2, 2023 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (2)
Interagency Patent Coordination and Improvement Act of 2023
Display title, Short title · Introduced in Senate, Reported to Senate
A bill to amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.
Official title · Introduced in Senate